Published in Cancer Weekly, October 9th, 1995
"Early animal studies of SU101 have demonstrated potential in treating a number of malignancies in patients with reduced side effects," explained Daniel Von Hoff, Director of the Institute for Drug Development of CTRC. "With the current trial, CTRC will...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.